Asset Details
Do you wish to reserve the book?
Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis
Do you wish to request the book?
Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis
2017
Overview
Cholestatic liver fibrosis is caused by obstruction of the biliary tract and is associated with early activation of portal fibroblasts (PFs) that express Thy-1, fibulin 2, and the recently identified marker mesothelin (MSLN). Here, we have demonstrated that activated PFs (aPFs) and myofibroblasts play a critical role in the pathogenesis of liver fibrosis induced by bile duct ligation (BDL). Conditional ablation of MSLN+ aPFs in BDL-injured mice attenuated liver fibrosis by approximately 50%. Similar results were observed in MSLN-deficient mice (Msln-/- mice) or mice deficient in the MSLN ligand mucin 16 (Muc16-/- mice). In vitro analysis revealed that MSLN regulates TGF-β1-inducible activation of WT PFs by disrupting the formation of an inhibitory Thy-1-TGFβRI complex. MSLN also facilitated the FGF-mediated proliferation of WT aPFs. Therapeutic administration of anti-MSLN-blocking Abs attenuated BDL-induced fibrosis in WT mice. Liver specimens from patients with cholestatic liver fibrosis had increased numbers of MSLN+ aPFs/myofibroblasts, suggesting that MSLN may be a potential target for antifibrotic therapy.
Publisher
American Society for Clinical Investigation
Subject
/ Bile
/ Calcium-Binding Proteins - genetics
/ Calcium-Binding Proteins - metabolism
/ Extracellular Matrix Proteins - genetics
/ Extracellular Matrix Proteins - metabolism
/ Female
/ GPI-Linked Proteins - genetics
/ GPI-Linked Proteins - metabolism
/ Humans
/ Liver
/ Liver Cirrhosis, Biliary - genetics
/ Liver Cirrhosis, Biliary - metabolism
/ Liver Cirrhosis, Biliary - pathology
/ Male
/ Membrane Proteins - genetics
/ Membrane Proteins - metabolism
/ Mice
/ Mucins
/ Rodents
/ Studies
